



EUROPEAN REGISTRY OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS IN FAILURE AFTER IMATINIB THERAPY

By European Leukemia Net
CML WP4

Study coordinators:

F. Guilhot, M. Gardembas, P. Rousselot, F. Nicolini, F. Maloisel, FX. Mahon,
A. Hocchaus, C. Preudhomme, J. Guilhot, G. Rosti

Registration – Phase A

Aims: collect already existing cases of failure patients that have been defined as « IFP » according to the definitions. The characteristics of the IFP patients at diagnosis will be collected together with cytogenetic and molecular data.

INVESTIGATOR

Investigator _____
Center _____
Address _____
Phone number _____
Fax _____
Email _____

PATIENT

Surname (Family name) /_/_/_/
Name (First name) /_/_/
Gender Male
 Female
Date of birth /_/_/_/ /_/_/_/_/_/_/ (month, year)
Date of diagnosis of CML /_/_/_/ /_/_/_/_/_/_/_/_/_/_/
Clinical Trial with Glivec® at time of failure No
 Yes

Reason for registration:

- Hematological relapse
- Cytogenetic relapse or progression (Increase in the Ph⁺ bone marrow cells by at least 50% points from the best achieved response)
- Progression at any time (Accelerated phase or blast crisis)
- Treatment discontinuation for toxicity
- No complete hematological response after 3 months
- Not any significant cytogenetic response after 6 months of therapy
- No major cytogenetic response after 12 months of therapy

Please, return this form at the Clinical Research Unit Fax: (33) 5 49 44 38 63